Merck & Company, Inc.
Long

Eisai And Merck Announce FDA Approval Of LENVIMA®

62
MRK: Merck
2018-08-16 16:11:00
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.